8-K: Tenon Medical Appoints Kevin Williamson as Chief Financial Officer

Tenon Medical has appointed Kevin Williamson as its new Chief Financial Officer, effective September 3, 2024, succeeding Steve Van Dick's retirement.

Summary

• Tenon Medical has hired Kevin Williamson as their new Chief Financial Officer, effective September 3, 2024.
• Mr. Williamson will receive an annual base salary of $315,000.
• He is eligible for an annual bonus of up to 30% of his base salary, prorated for 2024.
• The company will recommend a grant of 50,000 restricted stock units (RSUs) to Mr. Williamson, vesting over three and a half years.
• One-third of the RSUs will vest after 12 months, and the remaining two-thirds will vest semi-annually over the next four half-year periods.
• If terminated without cause, Mr. Williamson will receive 12 months of severance pay at his base salary rate.
• Mr. Williamson's previous experience includes CFO roles at Accelus Inc. and various finance positions at NuVasive, Inc.

Sentiment

Score: 8

Explanation: The document reflects a positive development for the company with the appointment of an experienced CFO. The terms of the offer are standard and fair, indicating a stable and well-managed company.

Positives

• Tenon Medical has secured an experienced CFO with a strong background in the medical device industry.
• Kevin Williamson's previous roles at Accelus and NuVasive demonstrate his expertise in finance and investor relations.
• The offer letter includes a competitive compensation package with a base salary, bonus potential, and equity awards.
• The severance package provides a safety net for Mr. Williamson in case of termination without cause.

Negatives

• The bonus is discretionary and dependent on both company and individual performance.
• The vesting of the RSUs is contingent on continued employment, meaning they could be forfeited if he leaves before vesting.
• The employment is at-will, meaning either party can terminate the relationship at any time.

Risks

• The company's performance and Mr. Williamson's individual performance will determine the amount of his annual bonus.
• The vesting of the RSUs is subject to continued employment, creating a risk of forfeiture if employment is terminated before vesting.
• The at-will employment agreement means that either party can terminate the relationship at any time, which could lead to instability.
• The company's financial distress could lead to termination of employment without severance.

Future Outlook

Tenon Medical anticipates that Kevin Williamson's financial leadership will be instrumental in advancing the company into its next phase of growth, particularly as they approach the completion of their post-market clinical trial and the release of its interim analysis.

Management Comments

• Steve Foster, CEO of Tenon, stated that they are thrilled to welcome Kevin Williamson as CFO due to his extensive track record in the spinal related medical technology industry.
• Kevin Williamson said it is an honor to join Tenon and he looks forward to leveraging his financial oversight experience to manage sustainable revenue and create operating leverage.

Industry Context

This appointment is in line with Tenon Medical's growth strategy, as they bring in an experienced CFO to manage their finances and investor relations. The medical device industry is competitive, and having a strong financial leader is crucial for success.

Comparison to Industry Standards

• The base salary of $315,000 for a CFO position at a company like Tenon Medical is within the typical range for similar roles in the medical device industry.
• The 30% target bonus is also a common incentive structure for executive roles.
• The equity grant of 50,000 RSUs is a standard practice to align the CFO's interests with the company's long-term performance.
• Companies like NuVasive and Accelus, where Mr. Williamson previously worked, are comparable in size and focus, suggesting that his experience is directly relevant to Tenon's needs.
• Severance packages of 12 months' salary are also common for executive-level positions, providing a safety net in case of termination without cause.

Management Changes

Stakeholder Impact

• Shareholders will likely view the appointment of an experienced CFO positively, potentially increasing investor confidence.
• Employees may see this as a sign of stability and growth for the company.
• Customers and suppliers may not be directly impacted by this change, but a strong financial leader can help ensure the company's long-term viability.

Next Steps

• Kevin Williamson will begin his role as CFO on September 3, 2024.
• The company will recommend to the Board that Mr. Williamson be granted the 50,000 restricted stock units.
• Tenon Medical will continue its national launch of the Catamaran SI Joint Fusion System.
• The company will complete the enrollment of its post-market clinical trial and release the study's interim analysis.

Key Dates

Keywords

Chief Financial Officer, CFO, Kevin Williamson, Tenon Medical, Medical Device, Finance, Compensation, Restricted Stock Units, Severance, Employment Agreement